Improving Biomarker Discovery and Development in Urothelial Carcinoma
Petros Grivas, MD, PhD, discusses the challenge with biomarker discovery currently in the treatment landscape of urothelial carcinoma.
Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology, and clinical director, Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the challenge with biomarker discovery currently in the treatment landscape of urothelial carcinoma.
The current challenge is that there are multiple different biomarkers, different assays, and different scoring algorithms being used in clinical trials, Grivas says. This makes biomarker discovery a great exercise, and we continue to discover more biomarkers. However, the challenge is with biomarker validation.
Grivas says whether to lock down biomarker assays could be prospectively validated to evaluate clinical utility of certain biomarkers. In the future, a feasible reproducible biomarker is needed to be used in prospective studies. The data presented at ESMO provide researchers with more knowledge to move the field forward.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
